Trial Profile
A Study Assessing the Clinical Efficacy and Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors(iPCSK9: Alirocumab and Evolocumab) in Patients with Heterozygous Familial Hypercholesterolemia (FH) or Atherosclerotic Cardiovascular Disease (ACVD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Apr 2018
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary) ; Evolocumab (Primary)
- Indications Atherosclerosis; Hyperlipoproteinaemia type IIa
- Focus Adverse reactions; Therapeutic Use
- 04 Apr 2018 New trial record